Even so, broadening the range of trials’ participants can be practically useful, because they may lead to new medical ...

Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...

And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...